摘要
目的探讨同步放化疗联合阿帕替尼治疗Ⅲ期不可切除的非小细胞肺癌(NSCLC)的效果。方法选取2016年1月至2018年1月郑州大学第一附属医院收治的90例Ⅲ期NSCLC患者,根据治疗方法将其分为对照组和观察组,各45例。对照组接受放疗同步依托泊苷联合顺铂方案化疗,观察组在对照组基础上口服阿帕替尼治疗。对比两组不良反应和疗效。结果观察组高血压和手足皮肤反应的发生率均高于对照组,差异有统计学意义(均P<0.05);两组骨髓抑制、消化道反应、放射性肺炎、放射性食管炎发生率比较,差异无统计学意义(均P>0.05)。两组近期疗效比较,差异无统计学意义(P>0.05);观察组中位总生存时间(OS)长于对照组,差异有统计学意义(P<0.05)。结论阿帕替尼联合标准同步放化疗在不影响放化疗进程的同时可延长局部晚期NSCLC患者的中位OS,是治疗Ⅲ期不可切除的NSCLC的可选方案之一。
Objective To explore the effect of concomitant radiochemotherapy combined with apatinib in the treatment of phaseⅢunresectable non-small cell lung cancer(NSCLC).Methods A total of 90 patients with stage Ⅲ NSCLC in the First Affiliated Hospital of Zhengzhou University from January 2016 to January 2018 were selected.The patients were divided into control group and observation group,according to treatment method.Control group received radiotherapy with simultaneous etoposide plus cisplatin regimen chemotherapy.Observation group took apatinib orally on the basis of control group.The adverse reactions and therapeutic effects between the two groups were compared.Results The incidences of hypertension and hand and foot skin reactions in observation group were higher than those in control group,and the differences were statistically significant(both P<0.05).There were no statistical differences between the two groups in the incidences of bone marrow suppression,digestive tract reaction,radiation pneumonitis and radiation esophagitis(all P>0.05).There was no statistical difference in the short-term efficacy between the two groups(P>0.05).The median overall survival(OS)of observation group was longer than that of control group,and the difference was statistically significant(P<0.05).Conclusion Apatinib combined with standard concurrent radiotherapy and chemotherapy can prolong the median OS of locally advanced NSCLC patients without affecting the course of radiotherapy and chemotherapy.It will be one of the options in the treatment of stageⅢunresectable NSCLC.
作者
杨想想
刘俊启
顾浩
樊锐太
YANG Xiang-xiang;LIU Jun-qi;GU Hao;FAN Rui-tai(Department of Radiotherapy,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China)
出处
《河南医学研究》
CAS
2020年第1期30-32,共3页
Henan Medical Research
基金
国家自然基金青年项目(81703158)
河南省高等学校重点科研项目(19A320036)
关键词
非小细胞肺癌
阿帕替尼
放疗
化疗
non-small cell lung cancer
apatinib
radiotherapy
chemotherapy
